

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

|                               |   |
|-------------------------------|---|
| <b>Drug</b>                   | <b>mifepristone and misoprostol</b>   |
| Brand Name                    | Mifegymiso  |
| Dosage Form(s)                | Kit (1 tablet of mifepristone 200 mg and 4 tablets of misoprostol 200 mcg)  |
| Manufacturer                  | Celopharma Inc.   |
| <b>Submission Type</b>        | <b>New Submission</b>   |
| Use Reviewed                  | For medical termination of a developing intra-uterine pregnancy with a gestational age up to 49 days as measured from the first day of the Last Menstrual Period (LMP) in a presumed 28-day cycle.  |
| Common Drug Review (CDR)      | Yes, CDR recommended: <b>Reimburse</b> . Visit the CDR website for more details: <a href="http://www.cadth.ca/sites/default/files/cdr/complete/SR0502_complete_Mifegymiso-Apr-20-17-e.pdf">www.cadth.ca/sites/default/files/cdr/complete/SR0502_complete_Mifegymiso-Apr-20-17-e.pdf</a>   |
| Drug Benefit Council (DBC)    | DBC met on May 1, 2017. In their review, the DBC considered various inputs including the CDR Clinical and Pharmacoeconomic reviews, the recommendation from the CDEC, a Patient Input Questionnaire response from one patient, CDR patient input, Clinical Practice Reviews from one specialist and one general physician, and a Budget Impact Assessment.  |
| <b>Drug Coverage Decision</b> | <b>Regular Benefit</b>  |
| Date                          | July 11, 2017   |
| Reason(s)                     | <p><b>Drug coverage decision is consistent with the DBC recommendation.</b></p> <ul style="list-style-type: none"> <li>Based on five trials, the regimen of oral mifepristone followed by buccal misoprostol 24 to 72 hours later was effective at inducing complete abortion without surgical intervention at any time in women of child-bearing age voluntarily seeking medical abortion with gestational age up to 56 to 63 days.</li> <li>Adverse events experienced by women in the studies were consistent with the known effects of prostaglandins.</li> <li>The cost of a course of therapy for Mifegymiso is higher than that of off-label options commonly used for medical abortion, but less than the cost of a surgical abortion.</li> </ul> |
| Other Information             | None  |

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.